Showing 14 posts of 14 posts found.


Mylan reaches agreement with Aspen for their European thrombosis business

September 8, 2020
Manufacturing and Production Mylan, aspen

Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s thrombosis business for €641.9 million.  …


South Africa’s over-charging case against Aspen dissolves, remains against big names

October 6, 2017
Medical Communications, Sales and Marketing Genentech, Pfizer, Roche, aspen, biotech, drugs, pharma, pharmaceutical

South Africa’s Competition Commission has admitted that there is no case to be heard against Aspen and Equity, in regards …


Regulators get aggressive on matters excessive

June 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CMA, Drug pricing, European Commission, Pfizer, aspen

Gustaf Duhs, Partner at Stevens & Bolton, discusses the recent cases of regulators becoming firmer with drug companies over their …

European Commission targets Aspen over 1,500% price hikes

May 16, 2017
Manufacturing and Production, Sales and Marketing European Commission, aspen

The European Commission (EC) has opened its first investigation over drug pricing following alleged hiking by pharma company Aspen, which …


Top Ten articles in the Pharma Industry this week

September 16, 2016
Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto

As we come to the end of another week, we’re looking back at an exciting week in the industry; there …

AstraZeneca sells rights to anaesthetics products to Aspen for $520 million upfront

June 9, 2016
Research and Development, Sales and Marketing AstraZeneca, Licencing, anaesthetics, aspen, marketing agreement

UK drug firm AstraZeneca (LSE: AZN) on Thursday said it has agreed to sell rights for its anaesthetics portfolio to Aspen …

Pharma M&A trail continues as Pfizer buys slice of Dutch biotech

May 12, 2015
Sales and Marketing Endo, Pfizer, aspen, merger

Pfizer has acquired a minority equity interest in the biotech firm AM-Pharma, and secured an exclusive option to acquire the …

GSK image

GSK sells off stake in Aspen for $853m

March 13, 2015
Sales and Marketing Africa, China, GSK, Novartis, Singapore, aspen, merger, redfern

GlaxoSmithKline has sold off half its stake in South Africa’s Aspen Pharmacare in a move that will net the British …

gsk image

GSK sells off non-core assets

January 6, 2014
Sales and Marketing GSK, Suntory, aspen, lucozade, ribena

GlaxoSmithKline has completed the offloading of several of its non-core assets in moves which stand to net the pharma manufacturer …

GSK image

GSK makes £425 million Aspen sale

November 21, 2013
Sales and Marketing GSK, Merck, South Africa, aspen

GlaxoSmithKline has raised £425 million with the sale of 28.2 million shares that it has in Africa’s biggest drugmaker as …

gsk image

Aspen buys GSK plant and thrombosis drugs for $1.1 billion

October 1, 2013
Manufacturing and Production, Sales and Marketing GSK, aspen

South African drugmaker Aspen Pharmacare has signed another combined brand and manufacturing facility deal, this time taking on GlaxoSmithKline’s thrombosis …

Merck image

Aspen buys Merck facility and products in $1 billion deal

July 1, 2013
Manufacturing and Production MSD, Merck, Oss, aspen

Africa’s largest drugmaker Aspen Pharmacare has agreed to buy a manufacturing facility owned by Merck & Co, plus a portfolio …

GSK image

GSK mulling sales of thrombosis brands and facility to Aspen

June 24, 2013
Manufacturing and Production, Sales and Marketing Arixtra, GSK, aspen

GlaxoSmithKline says it is considering an offer from South African drugmaker Aspen Pharmacare to take ownership of two thrombosis drugs …

GSK image

GSK receives thrombosis offer

June 19, 2013
Sales and Marketing GSK, aspen, thrombosis

GlaxoSmithKline has received an offer from South African firm Aspen Global Incorporated (AGI) to buy its injectable thrombosis treatments and …

Latest content